Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZGWEK)
| ADC Name |
XB010
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
XB010
Click to Show/Hide
|
|||||
| Organization |
Exelixis (Originator);Catalent (Top20 MNC);Invenra
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-5T4 antibody
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
RED-601 linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Oesophageal cancer | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Head and neck cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18; ECOG 0-1; adequate organ function; histologically confirmed advanced/metastatic solid tumors (NSCLC, HR+ BC, HNSCC, ESCC, TNBC); protocol compliance capability with signed informed consent.
|
||||
| Administration Dosage |
IV administration of XB010
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06545331 | Clinical Status | PHASE1 | ||
| Clinical Description | A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include MTD/RDE determination (18 months), safety profile (AE/SAE incidence), tolerability (exposure duration/dose intensity), and preliminary antitumor activity (ORR per RECIST 1.1) for XB010 monotherapy and combination therapy.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (Cmax, Tmax, clearance, AUC, Cmin) and immunogenicity (ADA analysis) for both dose-escalation (18 months) and cohort-expansion stages (24 months), along with continued tolerability assessments.
|
||||